» Articles » PMID: 29600623

[Effect and Mechanism of Mahuang Tang Against Influenza A/H1N1 Virus ]

Overview
Date 2018 Mar 31
PMID 29600623
Citations 5
Authors
Affiliations
Soon will be listed here.
Abstract

To study the effect and underlying mechanism of Mahuang Tang against influenza A virus , the influenza virus-infected Madin-Darby canine kidney(MDCK) cells were used as the carrier in this study to detect the median tissue culture-infective dose(TCID₅₀) of influenza A virus strains(A/PR8/34) on MDCK cells with cytopathic effect(CPE) assay. Blocking influenza virus invading host cells and anti-influenza virus biosynthesis were used as two different administration methods, and then the methyl thiazolyl tetrazolium(MTT) assay was utilized to determine the antiviral effective rate(ER), median efficacious concentration(EC₅₀) and therapeutic index(TI) of Mahuang Tang. The quantitative Real-time polymerase chain reaction(RT-PCR) was used to measure virus load and the mRNA expression levels of TLR4, TLR7, MyD88 and TRAF6 in MDCK cells at 24, 48 h after the treatment. The experiment results indicated that TCID₅₀ of A/PR8/34 for MDCK cells was 1×10-4.32/mL. The EC₅₀ values of two different treatment methods were 4.92,1.59 g·L⁻¹ respectively, the TI values were 12.53, 38.78 respectively, and when the concentration of Mahuang Tang was 5.00 g·L⁻¹, ER values were 50.21%, 98.41% respectively, showing that Mahuang Tang can block influenza virus into the host cells and significantly inhibit their biosynthesis. Meanwhile, as compared with the virus group, the virus load was significantly inhibited in Mahuang Tang groups, and Mahuang Tang high and middle doses had the significant effect on decreasing the mRNA expression of TLR4, TLR7,MyD88 and TRAF6 at 24, 48 h after the treatment. It can be demonstrated that the mechanisms of Mahuang Tang against influenza A virus are related to the inhibition of influenza virus replication and the mRNA expression of correlative genes in TLR4 and TLR7 signaling pathways.

Citing Articles

Effectiveness of seven oral traditional Chinese medicines against mild or moderate COVID-19: An updated systematic review and network meta-analysis.

Zhang T, Li T, Zhao F, Li T, Zhang M, Jin P Heliyon. 2024; 10(15):e35081.

PMID: 39170141 PMC: 11336365. DOI: 10.1016/j.heliyon.2024.e35081.


Role of Traditional Chinese Medicine in the Management of Viral Pneumonia.

Xi S, Li Y, Yue L, Gong Y, Qian L, Liang T Front Pharmacol. 2020; 11:582322.

PMID: 33192523 PMC: 7642817. DOI: 10.3389/fphar.2020.582322.


Reflections on treatment of COVID-19 with traditional Chinese medicine.

Luo H, Gao Y, Zou J, Zhang S, Chen H, Liu Q Chin Med. 2020; 15:94.

PMID: 32905189 PMC: 7468089. DOI: 10.1186/s13020-020-00375-1.


Principles and treatment strategies for the use of Chinese herbal medicine in patients at different stages of coronavirus infection.

Huang S, Lai H, Lin Y, Huang W, Hung H, Ou S Am J Cancer Res. 2020; 10(7):2010-2031.

PMID: 32774998 PMC: 7407358.


Screening of Antiviral Components of Ma Huang Tang and Investigation on the Ephedra Alkaloids Efficacy on Influenza Virus Type A.

Wei W, Du H, Shao C, Zhou H, Lu Y, Yu L Front Pharmacol. 2019; 10:961.

PMID: 31551774 PMC: 6747051. DOI: 10.3389/fphar.2019.00961.